 |
 |
On 15 Apr 2000, at 23:44, Hans van der Genugten wrote: > Neurology 2000 Mar 28;54(6):1272-6 > > APOE and the risk of PD with or without dementia in a population-based > study. > > Harhangi BS, de Rijk MC, van Duijn CM, Van Broeckhoven C, Hofman A, Breteler > MM > > Department of Epidemiology & Biostatistics, Erasmus Medical Center > Rotterdam, > The Netherlands. > > OBJECTIVE: > To study the association between APOE genotype and PD with or without > dementia. > > METHODS: > The study formed part of the Rotterdam Study, a prospective, > population-based cohort study on the frequency, etiology, and prognosis of > chronic diseases. The cohort examined for PD consisted of 6,969 > independently > living or institutionalized inhabitants from a suburb of Rotterdam, the > Netherlands, aged 55 years or older. All participants were screened at > baseline (1990 to 1993) and at follow-up (1993 to 1994) for symptoms of > parkinsonism by study physicians; screen positives received a diagnostic > workup by a neurologist. > > RESULTS: APOE genotyping was available for 107 PD patients (26 with and 81 > without dementia) and 4,805 non-PD control subjects. The presence of at > least one epsilon2 allele significantly increased the risk of PD (OR = 1.7; > 95% CI, 1.0 to 2.8). When we looked separately for demented and nondemented > PD patients as compared with nonparkinsonian controls, APOE did not appear > to be associated with PD without dementia, but both the epsilon2 and the > epsilon4 allele increased the risk of PD with dementia (OR = 5.6; 95% CI, > 2.0 to 15.2 and OR = 3.6; 95% CI, 1.3 to 9.9). The risk of dementia for > epsilon4 allele carriers was not significantly different for persons with or > without PD. However, the epsilon2 allele strongly increased the risk of > dementia in patients with PD (interaction p < 0.007). > > CONCLUSIONS: In the elderly the APOE-epsilon2 allele increases the risk of > PD and, in particular, the risk of PD with dementia. [log in to unmask]